Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

An update on psychopharmacological treatment of Body Dysmorphic Disorder (BDD)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Anorexia Nervosa and Motivation for Behavioral Change - Can it be Enhanced?

    Research output: Contribution to journalReviewResearchpeer-review

  2. A Brief Review of the Biology of Anorexia Nervosa

    Research output: Contribution to journalReviewResearchpeer-review

  3. The Diagnostic Work-Up of Eating Disorders

    Research output: Contribution to journalReviewResearchpeer-review

  1. Slime-loving bacteria from fresh faeces may be able to help anorexia patients

    Research output: Contribution to journalJournal articleCommunication

  2. Hvorfor fravælger halvdelen behandling for en spiseforstyrrelse?

    Research output: Contribution to journalContribution to newspaper - Newspaper articleCommunication

  3. On motivation as a Target for Intervention in Anorexia Nervosa

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A systematic review of blood-based serotonergic biomarker in Bulimia Nervosa

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Increased lipid and lipoprotein concentrations in anorexia nervosa: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations
Background: Body Dysmorphic Disorder (BDD) is a common, often severe disorder
characterized by appearance concerns and a preoccupation with thinking and behaviors
related to this concern. Population-based investigations have found a prevalence of BDD of
1.5-2% in the general population. The first-line of treatment for BDD is usually Selective
Serotonin Reuptake Inhibitors (SSRI) which often alleviates suicidal thinking, and act
to protect against further aggravation of suicidal thinking. For delusions, antipsychotic
treatment is usually required. This review provides an update on guidelines and
pharmacological treatment studies of BDD including recommendations for management
and treatment.
Material and method: A narrative review of the current literature.
Results: A presentation of guidelines, some key studies and recommendations for
pharmacological treatment of BDD.
Conclusion: Only one placebo controlled efficacy trial has been done finding that fluoxetin
is superior to placebo in treatment of BDD. Several open trials support this finding and a
randomized trial have found SSRI to reduce time to relapse. Clinical experiences suggest
SSRI may reduce risk of suicidality. In severe cases, add-on treatment of second generation
anti-psychotics may alleviate psychotic symptoms.
Original languageEnglish
JournalJournal of Psychology and Clinical Psychiatry
Volume10
Issue number6
Pages (from-to)228-232
Number of pages5
ISSN2373-6445
DOIs
Publication statusPublished - 25 Nov 2019

ID: 59087073